The FDA has granted clearance to Cynosure’s TriActive LaserDermology System, which is a cellulite treating system based on laser. In addition to the system’s apparent effect on cellulite, it also relives patients of minor pain and muscle spasms. TriActive LaserDermology System improves circulation as well and can be used with various plastic surgery procedures.

DUSA Pharmaceuticals Inc. has announced the completion for the enrollment of acne Phase IIb trial. The company plans to study the effects of multiple broad area photodynamic therapy (PDT) treatments, Levulan®, Kerastick® and BLU-U® brands as compared to the use of BLU-U® alone. Thus, the company will be able to evaluate the incremental advantage of Levulan® along with BLU-U® blue light therapy in acne treatment.

The Food and Drug Administration (FDA) has approved a drug that reverses the numbing effects of local anesthesia used by dentists. OraVerse, which was developed by Novalar Pharmaceuticals Inc. is the first dental anesthesia reversal agent on the market for patients of age 6 years or more. According to clinical studies, OraVerse reduces the time it takes for the effect of Novocaine and other numbing agents to wear off to half. Novalar aims to start selling the product in October.